Your browser is no longer supported. Please, upgrade your browser.
Settings
WVE [NASD]
Wave Life Sciences Ltd.
Index- P/E- EPS (ttm)-3.09 Insider Own4.92% Shs Outstand49.97M Perf Week-6.40%
Market Cap225.47M Forward P/E- EPS next Y-2.23 Insider Trans0.00% Shs Float48.36M Perf Month-28.73%
Income-143.10M PEG- EPS next Q-0.64 Inst Own73.70% Short Float2.62% Perf Quarter-24.57%
Sales15.70M P/S14.36 EPS this Y33.20% Inst Trans0.06% Short Ratio3.34 Perf Half Y-28.96%
Book/sh0.44 P/B9.98 EPS next Y21.60% ROA-55.10% Target Price9.86 Perf Year-42.58%
Cash/sh2.80 P/C1.57 EPS next 5Y- ROE-215.50% 52W Range4.16 - 12.17 Perf YTD-44.22%
Dividend- P/FCF- EPS past 5Y-15.90% ROI-184.20% 52W High-63.93% Beta0.51
Dividend %- Quick Ratio3.40 Sales past 5Y165.60% Gross Margin- 52W Low5.53% ATR0.31
Employees217 Current Ratio3.40 Sales Q/Q-6.70% Oper. Margin- RSI (14)36.45 Volatility6.15% 6.92%
OptionableYes Debt/Eq0.00 EPS Q/Q32.60% Profit Margin- Rel Volume0.39 Prev Close4.40
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume379.09K Price4.39
Recom2.30 SMA20-6.92% SMA50-19.64% SMA200-38.12% Volume148,080 Change-0.23%
Dec-15-20Resumed H.C. Wainwright Buy $20
Oct-23-20Initiated RBC Capital Mkts Sector Perform $13
Dec-31-19Downgrade SVB Leerink Outperform → Mkt Perform $33 → $10
Nov-01-19Initiated Guggenheim Buy $43
Jul-15-19Initiated Cowen Market Perform
Apr-17-19Reiterated H.C. Wainwright Buy $49 → $33
Aug-07-18Initiated Stifel Buy $56
Jul-23-18Initiated H.C. Wainwright Buy $49
Mar-19-18Reiterated Mizuho Buy $34 → $65
Feb-15-17Initiated H.C. Wainwright Buy $41
Nov-10-16Resumed Leerink Partners Outperform
Dec-07-15Initiated Sun Trust Rbsn Humphrey Buy $26
Dec-07-15Initiated Leerink Partners Outperform $20
Dec-07-15Initiated JMP Securities Mkt Outperform $52
Dec-07-15Initiated Jefferies Buy $28
Oct-19-21 06:54AM  
Oct-18-21 05:00PM  
Oct-06-21 01:32PM  
Sep-29-21 08:30AM  
07:21AM  
Sep-28-21 04:05PM  
Sep-22-21 04:05PM  
Sep-20-21 11:50AM  
Sep-09-21 08:30AM  
Sep-08-21 08:30AM  
Sep-07-21 04:05PM  
08:30AM  
Aug-07-21 04:33AM  
Aug-05-21 08:55AM  
07:30AM  
Jul-29-21 03:05PM  
Jul-26-21 04:05PM  
Jul-21-21 03:49PM  
Jul-20-21 08:00AM  
Jul-01-21 06:12AM  
Jun-03-21 08:10AM  
Jun-02-21 04:52PM  
May-28-21 08:30AM  
May-13-21 12:11PM  
07:30AM  
06:30AM  
May-10-21 04:05PM  
May-03-21 04:05PM  
Apr-26-21 01:39AM  
Apr-02-21 01:59AM  
Mar-30-21 02:04PM  
08:06AM  
05:38AM  
Mar-29-21 04:05PM  
Mar-23-21 08:50AM  
Mar-19-21 08:00AM  
Mar-16-21 09:12AM  
Mar-08-21 11:15AM  
Mar-04-21 10:25AM  
08:25AM  
07:20AM  
07:00AM  
06:15AM  
Feb-23-21 08:00AM  
Feb-16-21 05:00PM  
Feb-08-21 10:11AM  
Jan-12-21 08:47AM  
Jan-11-21 08:00AM  
Dec-02-20 08:00AM  
Nov-12-20 08:11AM  
Nov-10-20 08:00AM  
07:44AM  
Nov-09-20 05:30PM  
08:55AM  
08:14AM  
07:30AM  
06:30AM  
Nov-02-20 12:31PM  
Oct-26-20 04:05PM  
Oct-23-20 10:48AM  
Sep-28-20 04:05PM  
Sep-23-20 10:02AM  
07:00AM  
Sep-22-20 04:19PM  
04:01PM  
Sep-16-20 09:14AM  
Sep-15-20 08:20AM  
07:30AM  
Sep-10-20 04:25PM  
Aug-10-20 09:30PM  
08:45AM  
08:11AM  
07:30AM  
Aug-06-20 08:00AM  
Aug-03-20 12:31PM  
Jul-27-20 04:05PM  
12:31PM  
Jun-24-20 08:46AM  
Jun-18-20 05:14PM  
May-26-20 04:05PM  
May-18-20 07:30AM  
May-11-20 07:01PM  
08:55AM  
07:53AM  
07:30AM  
Apr-29-20 04:05PM  
Apr-23-20 07:01PM  
Apr-22-20 06:35PM  
Mar-24-20 10:38AM  
Mar-02-20 07:55AM  
06:45AM  
Feb-26-20 11:55AM  
Feb-24-20 12:30PM  
Feb-19-20 08:00AM  
Feb-18-20 08:00AM  
Feb-13-20 08:05AM  
Jan-22-20 11:48AM  
Jan-16-20 09:39AM  
Jan-14-20 09:55AM  
Dec-31-19 06:10AM  
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran KyleChief Financial OfficerMar 24Option Exercise2.4810,93027,10680,792Mar 24 07:45 PM
Francis ChrisSee RemarksFeb 16Sale10.572,69828,51878,462Feb 18 07:26 PM
BOLNO PAULPresident and CEOFeb 16Sale10.5711,205118,437410,976Feb 18 07:18 PM
Panzara Michael A.See RemarksFeb 16Sale10.572,92930,96086,420Feb 18 07:16 PM
Vargeese ChandraChief Technology OfficerFeb 16Sale10.573,14533,24385,412Feb 18 07:14 PM
Moran KyleChief Financial OfficerFeb 16Sale10.571,72218,20269,862Feb 18 07:09 PM